<code id='99D1EC678F'></code><style id='99D1EC678F'></style>
    • <acronym id='99D1EC678F'></acronym>
      <center id='99D1EC678F'><center id='99D1EC678F'><tfoot id='99D1EC678F'></tfoot></center><abbr id='99D1EC678F'><dir id='99D1EC678F'><tfoot id='99D1EC678F'></tfoot><noframes id='99D1EC678F'>

    • <optgroup id='99D1EC678F'><strike id='99D1EC678F'><sup id='99D1EC678F'></sup></strike><code id='99D1EC678F'></code></optgroup>
        1. <b id='99D1EC678F'><label id='99D1EC678F'><select id='99D1EC678F'><dt id='99D1EC678F'><span id='99D1EC678F'></span></dt></select></label></b><u id='99D1EC678F'></u>
          <i id='99D1EC678F'><strike id='99D1EC678F'><tt id='99D1EC678F'><pre id='99D1EC678F'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:7
          BiTE Bridge
          Illustration of a BiTE, Amgen's bispecific antibodies Amgen

          In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

          Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

          advertisement

          “We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

          6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

          read more
          The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO
          The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

          MollyFerguson/STATHappyGroundhogDayeve.SometakesandthoughtsonBluebirdBio’squestforgenetherapyprofits

          read more
          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more

          EU fines Illumina $475 million over Grail acquisition

          AdobeLONDON—TheEuropeanUniononWednesdayissuedanantitrustfineof$475milliontotheU.S.geneticsequencingg